Our leadership team, including recognized physician experts and researchers, is at the forefront of shaping new standards of cancer care based upon the latest research. Patients are at the heart of everything we do. Sarah Cannon offers integrated cancer services, providing patients with cutting-edge treatments and upholding the highest quality care for patients from diagnosis through survivorship.
Vice President, Strategic Development
Marcy Vallone joined Sarah Cannon in 2011 and serves as the Vice President of Strategic Development where she oversees the clinical research programs, alliance and strategic partnerships and business development activities for the research institute.
Vallone has nearly 20 years in clinical research experience primarily focused in early phase oncology. Prior to joining Sarah Cannon, Vallone conducted research for several pharmaceutical companies including Rigel Pharmaceuticals, Proteolix Inc., and Onyx Pharmaceuticals an Amgen subsidiary where she served as a key member of the Kyprolis clinical development team. She graduated from Washington State University with a Bachelor of Science in Microbiology and has been a co-author on seven publications and 29 abstracts.